What Analysts Are Saying About Novo Nordisk Stock
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00, and a low estimate of $105.00. A 8.65% drop is evident in the current average compared to the previous average price target of $159.00.
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...
Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...
EUROPE’S Stoxx 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...
Separately, the U.S. Food and Drug Administration approved Novo Nordisk's bleeding disorder drug Alhemo. Meanwhile, ...
European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback